Innovent Bio HKG:1801 – Hong Kong Blue Chip stock
Innovent Bio (HKG:1801)
Hong Kong Blue Chip Stock • Sector: Medicine
Next ex-dividend date: N/A
Innovent Biologics Inc. (1801.HK) is a leading Chinese biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative oncology, autoimmune, and metabolic disease therapies. The company has built a strong pipeline of biologic drugs and strategic partnerships, positioning itself as one of China’s most important biotech players listed on the Hong Kong Stock Exchange.
Stock Value Score
This score indicates whether the stock currently appears undervalued, fairly priced, or expensive,
based on key valuation metrics such as earnings, book value, and cash flow.
| P/E ratio | 112.89 |
| P/B ratio | 8.69 |
| EPS | 0.76 |
| Beta | 0.77 |
Beta above 1 suggests higher volatility. Below 1 suggests more stability relative to the market.
Based on current valuation metrics, the stock appears .
Future changes in earnings, cash flow, or price could materially shift this assessment.
Champion Members see the full 3-Pillar scorecard:
Dividend Growth,
Dividend Safety,
Stock Value.
